Healthcor Management Lp decreased Sarepta Therapeutics Inc (SRPT) stake by 40.81% reported in 2017Q3 SEC filing. Healthcor Management Lp sold 829,120 shares as Sarepta Therapeutics Inc (SRPT)’s stock rose 22.49%. The Healthcor Management Lp holds 1.20M shares with $54.56M value, down from 2.03 million last quarter. Sarepta Therapeutics Inc now has $3.74B valuation. The stock decreased 1.26% or $0.74 during the last trading session, reaching $57.81. About 1.87M shares traded or 10.78% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since January 5, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.
Gevo, Inc. (GEVO) formed triangle with $0.65 target or 7.00% below today’s $0.70 share price. Gevo, Inc. (GEVO) has $13.88 million valuation. The stock increased 14.57% or $0.0889 during the last trading session, reaching $0.6989. About 4.50M shares traded or 441.98% up from the average. Gevo, Inc. (NASDAQ:GEVO) has declined 85.24% since January 5, 2017 and is downtrending. It has underperformed by 101.94% the S&P500.
Investors sentiment increased to 2.88 in Q3 2017. Its up 1.36, from 1.52 in 2017Q2. It is positive, as 24 investors sold SRPT shares while 27 reduced holdings. 63 funds opened positions while 84 raised stakes. 51.70 million shares or 25.22% more from 41.29 million shares in 2017Q2 were reported. Emerald Mutual Fund Advisers Tru holds 716,772 shares. First Tru LP accumulated 57,668 shares. Wells Fargo & Co Mn stated it has 300,841 shares. Healthcor Mngmt Limited Partnership accumulated 1.20 million shares or 1.83% of the stock. Ny State Common Retirement Fund, a New York-based fund reported 63,300 shares. Hightower Advsrs Limited Liability holds 69,596 shares. Sectoral Asset Incorporated invested in 69,099 shares. Raymond James And Associate holds 24,881 shares. Sphera Funds Mngmt owns 384,997 shares. Savings Bank Of Montreal Can reported 84,604 shares. Parametric Port Ltd Liability Corp reported 136,098 shares stake. 317,800 were reported by Jpmorgan Chase And Company. California State Teachers Retirement Sys owns 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 94,770 shares. Sei Invs, Pennsylvania-based fund reported 22,338 shares. Ameritas Inv Prtn Inc invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).
Healthcor Management Lp increased Laboratory Corp Amer Hldgs (NYSE:LH) stake by 197,290 shares to 1.57 million valued at $237.37 million in 2017Q3. It also upped Humana Inc (NYSE:HUM) stake by 11,772 shares and now owns 260,870 shares. Livanova Plc was raised too.
Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 20 have Buy rating, 1 Sell and 6 Hold. Therefore 74% are positive. Sarepta Therapeutics had 94 analyst reports since August 5, 2015 according to SRatingsIntel. As per Monday, August 24, the company rating was upgraded by Piper Jaffray. The rating was maintained by TH Capital on Wednesday, August 26 with “Buy”. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Outperform” rating by Oppenheimer on Wednesday, April 6. The firm earned “Neutral” rating on Wednesday, April 20 by Janney Capital. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Wednesday, January 3 by Janney Capital. The rating was downgraded by Suntrust Robinson to “Neutral” on Friday, August 7. RBC Capital Markets maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Wednesday, March 1. RBC Capital Markets has “Outperform” rating and $91 target. The firm has “Outperform” rating by RBC Capital Markets given on Monday, September 19. Morgan Stanley maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, January 4 with “Equal-Weight” rating. The rating was maintained by Needham with “Buy” on Friday, October 2.
Since October 3, 2017, it had 0 insider purchases, and 1 insider sale for $575,000 activity. 11,500 shares valued at $575,000 were sold by Ruff Shamim on Tuesday, October 3.
Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on February, 27. They expect $-0.35 EPS, up 77.85% or $1.23 from last year’s $-1.58 per share. After $-0.78 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -55.13% EPS growth.
Analysts await Gevo, Inc. (NASDAQ:GEVO) to report earnings on April, 4. They expect $-0.26 earnings per share, up 77.19% or $0.88 from last year’s $-1.14 per share. After $-0.36 actual earnings per share reported by Gevo, Inc. for the previous quarter, Wall Street now forecasts -27.78% EPS growth.
Among 2 analysts covering Gevo (NASDAQ:GEVO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gevo had 5 analyst reports since August 19, 2015 according to SRatingsIntel. The stock of Gevo, Inc. (NASDAQ:GEVO) earned “Buy” rating by H.C. Wainwright on Wednesday, August 19. The rating was maintained by Rodman & Renshaw with “Buy” on Friday, January 13. The company was maintained on Wednesday, July 26 by H.C. Wainwright. The company was maintained on Friday, August 4 by H.C. Wainwright. The stock has “Buy” rating by Rodman & Renshaw on Wednesday, August 19.